Fortress Biotech Inc. is a Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products.
Fortress Biotech Inc. (FBIO) had a good day on the market for Wednesday March 31 as shares jumped 3.52% to close at $3.53. About 626,841 shares traded hands on 4,406 trades for the day, compared with an average daily volume of n/a shares out of a total float of 94.8 million. After opening the trading day at $3.46, shares of Fortress Biotech Inc. stayed within a range of $3.62 to $3.46.
With today’s gains, Fortress Biotech Inc. now has a market cap of $334.66 million. Shares of Fortress Biotech Inc. have been trading within a range of $5.08 and $1.74 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Fortress Biotech Inc. is based out of New York, NY and has some 93 employees. Its CEO is Lindsay A. Rosenwald.